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Abstract: Recent studies have shown that retinal neurodegeneration may precede visible vascular
changes in diabetic retinopathy (DR). In addition, the relationship of choroidal thickness (CT) with DR
stage is not well defined. To assess the inner retinal and choroidal structural changes in type 1 diabetic
subjects (T1D), a cross-sectional study was conducted in 242 T1D patients and in 69 age-matched,
non-diabetic individuals. The nasal retinal nerve fibre layer (RNFL) thickness was lower in T1D
patients without DR (p < 0.001), with mild DR (p < 0.001), and with advanced DR (p < 0.001) compared
to control subjects. The ganglion cell layer (GCL) thickness was lower in T1D patients with advanced
DR compared to those with mild DR (p = 0.003) and without DR (p < 0.001) and compared to the
control subjects (p < 0.001). T1D subjects with no DR and mild DR had higher CT than the control
subjects, but the CT in T1D patients with advanced DR was lower (p = 0.038) than that in T1D subjects
with mild DR and was not significantly different from that of the control subjects. In conclusion,
T1D subjects showed a significant thinning of the nasal RNFL in the early stages of the disease, even
before any vascular changes in the retina. A decrease in the GCL thickness during advanced DR
stages was observed. Choroidal thickness was higher in T1D subjects without DR and in early DR
stages but decreased in advanced stages.
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J. Clin. Med. 2019, 8, 1412; doi:10.3390/jcm8091412 www.mdpi.com/journal/jcm
J. Clin. Med. 2019, 8, 1412 2 of 13
1. Introduction
Diabetic retinopathy (DR) is one of the leading causes of visual impairment and preventable
blindness among the adult working-age population in developed countries. DR is a multifactorial
disease with many different risk factors, including glycated haemoglobin (HbA1c), blood pressure, and
serum lipid levels [1,2]. Classically, DR has primarily been considered a microvascular disorder in which
the initial manifestations include retinal microaneurysms, capillary alterations, and haemorrhaging.
These vascular alterations may lead to degeneration of the neuronal and glial structures of the
inner retina as the disease progresses. However, data from recent studies using spectral-domain
optical coherence tomography (SD-OCT) imaging suggest that morphological changes in retinal
neurodegeneration may precede any visible vascular changes [3–7]. In this regard, the earliest
neurodegenerative alterations occur in the main layers of the inner retina, as evidenced by the thinning
of the retinal nerve fibre layer (RNFL) and the ganglion cell complex (GCC) [4,6–8].
Choroidal alterations also play a key role in the pathophysiology of several retinal diseases,
including DR [9–12]. Choroidal thickness (CT) is considered a measure of choroidal blood flow, which
supplies the outer retinal layers. Several studies have described the presence of choroidal vasculopathy
in diabetic subjects [9,13–16]. However, those studies—most of which were performed in a paediatric
population—have reported contradictory findings, likely due to their small sample sizes. A similar
controversy exists for the presence of retinal neurodegeneration in subjects who have diabetes without
DR. The published data are contradictory, with some authors finding no differences in RNFL or
ganglion cell layer (GCL) thickness in patients with type 1 diabetes (T1D) without DR compared to
healthy control subjects [17,18], whereas other authors have described differences in these structures
between diabetic patients and control subjects [19]. In this context, the aims of the present study
were (1) to evaluate the retinal and choroidal structures in a large cohort of patients with T1D using
SD-OCT and (2) to determine whether retinal and choroidal alterations are correlated with the degree
of diabetic retinopathy.
2. Experimental Section
2.1. Patients
This was a cross-sectional study conducted in subjects diagnosed with T1D recruited from
outpatient clinics at two university hospitals within the same health care organization (Institut Català
de la Salut) in Catalonia, Spain.
The inclusion criteria for T1D subjects were as follows: (1) age ≥ 18 years, (2) diagnosis of T1D
with disease duration ≥ one year, (3) normal renal function (estimated glomerular filtration rate
> 60 mL/min), (4) urine albumin excretion rate < 300 mg/g, and (5) the absence of cardiovascular
disease (ischaemic heart disease, cerebrovascular disease, peripheral arterial disease, and heart failure)
or diabetic foot disease.
The control group consisted of 69 healthy age- and sex-matched volunteers. The selection criteria
for the control subjects were the same as those for the T1D subjects, except for the specific microvascular
complications (retinopathy and albuminuria). Additional inclusion criteria for the control subjects
were: (1) fasting glucose < 100 mg/dL and (2) HbA1c < 5.7%. Ophthalmologic exclusion criteria for
both groups included a refractive error of 5 dioptres or more, concomitant retinal diseases, ocular
inflammation, glaucoma, macular oedema, previous surgery (during the year before the exam), and
laser photocoagulation (during the six months before the exam).
The present subject sample was a subset of 340 T1D subjects included in a previously published
study aimed at assessing the association of subclinical carotid atherosclerotic disease with the presence
and severity of diabetic retinopathy [20]. For the current study, it was also important to exclude
patients with previous cardiovascular disease and/or chronic kidney disease, as these two conditions
are known to be associated with vascular damage. Of those 340 subjects, 98 were excluded from
the present study either because they did not undergo SD-OCT (n = 78) or due to the presence of
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ophthalmologic exclusion criteria (n = 20) as follows: glaucoma (n = 3); laser treatments in the previous
6 months (n = 2); myopia > 5 dioptres (n = 6); and proliferative diabetic retinopathy treated with
photocoagulation (n = 9). As a result, a total of 242 subjects were included in the current study.
2.2. Clinical Assessment
Serum and urine samples were collected in the fasting state. Subject characteristics (gender, age,
and ethnicity), anthropometric parameters (weight, height, body mass index, and waist circumference),
other parameters (hypertension, dyslipidaemia, smoking, medication, and disease duration) and
laboratory measurements (glucose, HbA1c, triglycerides, total/HDL/LDL cholesterol, creatinine, and
albumin/creatinine ratio), assessed using standard laboratory methods previously described, were
recorded [21].
2.3. Ophthalmic Examination
A complete ophthalmological evaluation, including retinopathy classification, was performed by
two expert ophthalmologists (MC and CJ) in both the patient and control groups. Optical coherence
tomography measurements were performed using spectral-domain OCT (Cirrus HD-OCT, model 4000,
Carl Zeiss Meditec, Dublin, CA, USA) to measure RNFL, GCL, and CT. Only SD-OCT scans with a
signal strength > 8 were used for the analysis. RNFL thickness was measured according to an Optic
Disc Cube 200 × 200 protocol, with the data calculated automatically by quadrant (temporal, superior,
nasal, inferior). Mean values were also calculated. The GCL thickness was measured (including mean
and minimum thicknesses) using the Macula Cube 512 × 128 protocol around the fovea. Choroidal
thickness was measured using enhanced-depth imaging (EDI-OCT) with a high-definition 5-line Raster
scan pattern. The measurements were made manually with a caliper in three positions (subfoveal, nasal,
and temporal to the fovea) at a distance of 2000 µm. Choroidal thickness was calculated as the vertical
distance between the first hyperreflective line (Bruch’s membrane) and the second hyperreflective line
(the internal surface of the sclera) [22].
DR was classified into five stages according to the Early Treatment Diabetic Retinopathy Study
(ETDRS) classification [23], as follows: (1) no apparent retinopathy, (2) mild non-proliferative
retinopathy (NPDR), (3) moderate NPDR, (4) severe NPDR, and (5) proliferative diabetic retinopathy
(PRD). Diabetic subjects with DR were reclassified into 2 stages (mild [ETDRS stages 1–2] or advanced
[ETDRS stages 3–4] DR). Additionally, subjects with SD-OCT choroid measurements of 2 or more
standard deviations above the mean value observed in the control group were classified as having a
thickening of the choroid. Further, subjects with SD-OCT RNFL measurements less than 2 standard
deviations below the mean value observed in the control group were classified as having a thinning
of the RNFL. For the analysis, we used the ophthalmological variables obtained for the right eye if
both eyes had the same DR grade. Otherwise, the variables from the eye with the highest DR grade
were selected.
The ethics committees of both participating centres approved the study, which was performed in
accordance with the principles of the Declaration of Helsinki. Written informed consent was obtained
from all participants.
2.4. Statistical Analysis
A descriptive between-group comparison was performed to assess homogeneity in the clinical
characteristics of the study population. Student’s t-test was performed to determine the significant
differences between two groups (T1D versus control) in the quantitative variables, and a Chi-square
test was used to compare qualitative variables between groups. Univariate and multivariate regression
models were performed to estimate the crude and adjusted associations. The multivariate results were
adjusted for sex, age, hypertension, dyslipidaemia, and body mass index (BMI).
The subanalysis in the T1D subjects was performed by examining the association between the DR
grade and the ophthalmological variables. Differences between groups were evaluated by analysis of
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variance (ANOVA), and p values were corrected using the post hoc Tukey test. Linear multivariate
regression models were performed to assess the associations for each ophthalmological variable.
Correction for multiple comparisons was performed using the Benjamini–Hochberg procedure (or
false discovery rate). The cut-off for statistical significance was set as p < 0.05. The statistical R package
(v. 3.5.1, Free Software Foundation, https://www.r-project.org/) was used for data management and to
perform the statistical analysis.
3. Results
The clinical characteristics of the study group are summarized in Table 1. Hypertension and
dyslipidaemia were more prevalent in the T1D group, who also had higher blood pressure (systolic and
diastolic) than the control subjects. There were no significant differences between groups in terms of age,
sex, ethnicity, smoking habits, BMI, waist circumference, creatinine levels, or urine/albumin/creatinine
ratios. The proportion of microalbuminuria was 3.3% (8/242) in T1D and 2.9% (2/69) in the control
group. The mean duration of T1D was 20.6 years.
Table 1. Clinical characteristics of the study population.
Variables 1 Control Type 1 Diabetes p Value
N 69 242 -
Age, years 45.1 (11.2) 44.5 (10.7) 0.668
Sex, male 30 (43.5%) 114 (47.1%) 0.692
Ethnicity, Caucasian 69 (100%) 239 (98.8%) 1.000
Current or former smoker 35 (50.7%) 128 (53.2%) 0.387
Antiplatelet agents 0 (0.00%) 67 (27.7%) <0.001
Dyslipidaemia 5 (7.25%) 95 (39.3%) <0.001
Hypertension 7 (10.1%) 58 (24.0%) 0.020
Systolic blood pressure, mmHg 118 (13.2) 126 (17.1) <0.001
Diastolic blood pressure mmHg 71.8 (9.38) 74.4 (10.0) 0.049
Body mass index, kg/m2 24.6 (3.62) 25.6 (4.05) 0.059
Waist circumference, cm 87.2 (11.0) 88.9 (12.6) 0.290
HbA1c, % 5.28 (0.31) 7.60 (1.03) <0.001
Total cholesterol, mg/dL 203 (30.8) 180 (28.9) <0.001
HDL cholesterol, mg/dL 59.9 (12.4) 64.3 (15.4) 0.017
LDL cholesterol, mg/dL 123 (29.3) 102 (24.2) <0.001
Triglycerides, mg/dL 103 (69.4) 74.4 (34.7) 0.002
Creatinine, mg/dL 0.79 (0.13) 0.77 (0.16) 0.151
Urine albumin/creatinine ratio, mg/g 7.65 (10.4) 7.02 (13.6) 0.684
Diabetes duration, years - 20.6 (10.4) -
1 All data are given as the mean (standard deviation) or n (%). Student’s t-test was used for quantitative variables
and Chi-square test for qualitative variables. HDL, high density lipoprotein; LDL, low density lipoprotein.
3.1. Ophthalmologic Examination
Of the 242 T1D subjects, 139 (57.4%) did not have DR, 74 (30.6%) had mild DR, and 29 (12%)
presented with advanced DR. The clinical variables of the study group according to DR grade are
shown in Table S1.
Nasal RNFL was significantly lower in all three T1D subgroups (i.e., those without DR, mild DR,
and advanced DR) (p < 0.001) than in the control group, contrary to what was observed in the superior
and inferior sectors, in which the RNFL was greater in the T1D subjects than in the control subjects
p = 0.004 and p < 0.001, respectively. No significant differences between the T1D subjects and control
subjects were observed in the temporal RNFL (p = 0.283) (Figure S1, Table S2). The proportion of
subjects with retinal thinning assessed in the RNFL in T1D subjects without DR was 1.5% (2/130) in the
superior sector, 0.8% (1/131) in the nasal sector, and 1.5% (2/131) in the inferior sector. The presence of
retinal thinning in subjects with advanced DR was 11.1% (1/9) in the superior sector, 0% (0/9) in the
nasal sector, and 22.2% (2/9) in the inferior sector.
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GCL thickness was significantly lower in T1D subjects with advanced DR versus T1D subjects
without DR (p < 0.001), subjects with mild DR (p = 0.010), and the control group (p < 0.001) (Table 2,
Figure 1). There were no significant differences in GCL between the T1D and control subjects (Table S2).
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Figure 1. Gan li ll layer (GCL) measur ments by spectral-domain optical coherence tomography:
(a) control subjects; (b) T1 subjects with mild DR; (c) type 1 diabetes (T1D) subjects without DR and
(d) T1D subjects with advanced diabetic retinopathy (DR). Colours shown in the GCL thickness sector
diagram should be interpreted as follows: white indicates expected values above 95%, green is between
5% and 95% (normal), yellow is from 1% to 5% (borderline), and red is below 1% (outside normal
limits). OD, right eye.
Choroidal thickness was also significantly greater in the subfoveal (p < 0.001), nasal (p < 0.001),
and temporal (p = 0.004) sectors in T1D subjects versus those in the control subjects (Figure 2). Up to
8.3% (11/133) of the T1D subjects without DR presented a thickening of the choroid. This proportion
of patients was observed in the three sectors analysed (temporal, nasal, and subfoveal). In relation
to the group of T1D subjects with mild DR, thickening was observed in 7.1% (5/70) of subjects in the
temporal sector, 17.1% (12/70) in the nasal sector and 10% (7/70) in the subfoveal sector. Choroidal
thickness was greater in the T1D subjects with mild DR and without DR compared to control subjects
(Figure 2), both for the subfoveal region (p = 0.006 and p < 0.001, respectively) and the nasal region
(p = 0.001 and p < 0.001, respectively). Temporal CT was greater only in patients with mild DR
(p = 0.005) versus control subjects. Temporal and nasal CT values were lower in T1D subjects with
advanced DR (p = 0.038 and p = 0.045, respectively) compared to T1D subjects with mild DR (Figure 3,
Table 2).
J. Clin. Med. 2019, 8, 1412 6 of 13
Table 2. Association between diabetic retinopathy grade and ophthalmological variables.
Variables 1 Control No DR Mild DR
Advanced
DR p Overall
p CT vs.
No DR
p CT vs.
Mild DR
p CT vs.
Adv. DR
p No DR
vs. Mild
DR
p No DR
vs. Adv.
DR
p Mild DR
vs. Adv.
DR
CT (subfoveal) 322 (92.6) 367 (93.8) 386 (97.7) 341 (83.7) <0.001 0.006 <0.001 0.812 0.549 0.526 0.148
CT (nasal) 228 (86.9) 278 (87.4) 300 (89.5) 249 (72.4) <0.001 0.001 <0.001 0.706 0.314 0.372 0.045
CT (temporal) 291 (76.2) 321 (80.5) 337 (81.8) 289 (76.3) 0.002 0.056 0.005 0.998 0.542 0.206 0.038
GCL (mean) 82.4 (6.6) 84.3 (7.2) 81.4 (10.8) 78.5 (18.8) 0.018 0.561 0.925 0.275 0.175 0.024 0.533
GCL (minimum) 79.6 (10.4) 80.7 (9.9) 77.8 (12) 68 (25.0) <0.001 0.932 0.821 <0.001 0.373 <0.001 0.003
RNFL (mean) 91.6 (9.8) 95.1 (10.7) 92.5 (19.3) 94.6 (16.7) 0.287 0.305 0.980 0.763 0.545 0.998 0.898
RNFL (temporal) 66.9 (12.5) 65.4 (10.1) 62.9 (13.3) 70.2 (16) 0.056 0.822 0.197 0.681 0.499 0.303 0.063
RNFL (superior) 110 (17.5) 116 (18.0) 119 (16.8) 120 (21) 0.026 0.104 0.035 0.141 0.837 0.852 0.995
RNFL (nasal) 110 (18.2) 75.9 (14.8) 75.5 (18.3) 76.4 (16.0) <0.001 <0.001 <0.001 <0.001 0.999 0.999 0.997
RNFL (inferior) 111 (17.7) 125 (19.1) 124 (23.9) 118 (31.0) <0.001 <0.001 0.003 0.484 0.954 0.471 0.725
1 All data are given as the mean (standard deviation), measure units in µm. Differences between groups were evaluated by analysis of variance (ANOVA), and p values were corrected
using the post hoc Tukey test. Adv., Advanced; CT, choroidal thickness; GCL, ganglion cell layer; RNFL, retinal nerve fibre layer.
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3.2. Ophthalmological Associations
The univariate analysis revealed significant associations of T1D with subfoveal, nasal, and
temporal CT and with RNFL thickness in the superior, nasal, and inferior sectors (Supplementary
Table S3). Additionally, in T1D subjects without DR, thickening of the choroid was associated with age
and smoking (p = 0.015 and p = 0.017, respectively) in the temporal sector and with smoking in the
nasal sector (p = 0.004). Furthermore, in T1D subjects with mild DR, thickening of the choroid was
associated with male gender in both the temporal sector (p = 0.017) and the subfoveal sector (p = 0.042)
and with age and smoking habits in the subfoveal sector (p = 0.035 and p = 0.007, respectively).
In the multivariate linear regression analysis, all of these associations remained statistically
significant after adjusting for clinical variables (sex, age, hypertension, dyslipidaemia, and BMI).
Choroidal thickness was greater in T1D subjects compared to control subjects in all sectors: 50 µm in
the subfoveal sector (β = 50.52; p < 0.001), 54 µm in the nasal sector (β = 54.99; p < 0.001), and 29 µm in
the temporal sector (β = 29.08; p = 0.020). For RNFL thickness, the nasal sector was thinner in T1D
patients compared to control subjects (β = −35.29, p < 0.001). However, RNFL values in the superior
and inferior sectors were higher in T1D patients than in control subjects (β = 5.76, p = 0.046; β = 12.00,
p < 0.001, respectively).
Multivariate regression analysis, performed to assess the association between the ophthalmological
variables and the DR grade (mild and advanced DR versus no DR), showed that the minimum GCL
was the only ophthalmological parameter independently associated with advanced DR. In this subject
group, the minimum GCL value was 11 µm lower (β = −11.34; p = 0.004) than in T1D subjects without
DR (Table 3). By contrast, no association was found between the DR grade and CT or RNFL values.
Table 3. Multivariate analysis of the association between the ophthalmological variables and the grade
of diabetic retinopathy in patients with type 1 diabetes.
Variables
Mild DR Advanced DR
Estimated β (SE) p Value Estimated β (SE) p Value
CT (subfoveal) 28.17 (13.31) 0.126 −7.52 (20.50) 0.892
CT (nasal) 28.84 (12.64) 0.126 −13.75 (19.46) 0.687
CT (temporal) 23.83 (11.40) 0.126 −17.46 (17.56) 0.535
GCL (mean) −2.39 (1.52) 0.330 −4.96 (2.36) 0.126
GCL (minimum) −2.06 (1.91) 0.514 −11.34 (2.98) 0.004
RNFL, mean −2.43 (2.12) 0.514 0.54 (3.34) 0.917
RNFL, temporal −2.48 (1.78) 0.412 6.99 (3.01) 0.126
RNFL, superior 2.23 (2.69) 0.629 1.17 (4.56) 0.917
RNFL, nasal −0.22 (2.43) 0.929 0.71 (4.11) 0.917
RNFL, inferior −1.34 (3.28) 0.892 −6.10 (5.56) 0.514
In the multivariate analysis, the estimated β coefficients are given after adjustment for the clinical variables (sex,
age, hypertension, dyslipidaemia, and body mass index), and p values were adjusted via the method of Benjamini
and Hochberg for multiple comparisons. SE, standard error; CT, Choroidal thickness; GCL, ganglion cell layer;
RNFL, retinal nerve fibre layer.
4. Discussion
In the present study, we found that, compared to control subjects, nasal RNFL thickness was
lower in T1D subjects, regardless of the DR grade. GCL thickness was also lower in the advanced DR
subgroup compared to subjects with mild DR or those without DR and to non-diabetic individuals.
On the other hand, choroidal thickness was higher in patients with no DR and mild DR compared
to the control subjects. Interestingly, CT was lower in subjects with advanced DR than in subjects
with mild DR and similar to the CT values in control subjects. Thus, we report a direct correlation
between choroidal alterations and the degree of retinopathy in T1D patients. Relatively few studies
have evaluated the association between inner retinal and choroidal changes with the degree of DR
in T1D patients [4–9,13,14,16,18,24]. Moreover, many of these studies were small, and most were
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performed in paediatric populations. Thus, the mean duration of diabetes was relatively short. To our
knowledge, this study included the largest cohort of T1D patients with an evaluation of structural
features of the retina by SD-OCT.
4.1. RNFL and GCL
There is evidence to suggest that retinal neurodegeneration begins early in the pathogenesis of
DR [3–8,19,24,25]. In the early stages of DR, before this complication becomes clinically evident, it is
not possible to detect microvascular abnormalities by ophthalmoscopic examination. However, in
these pre-clinical stages, the presence of abnormalities can be detected by multifocal electroretinogram
(mfERG) or SD-OCT [26]. Some authors have found no differences in the RNFL or GCL thickness using
SD-OCT in paediatric [17,18] or young [9] T1D subjects without DR when compared to non-diabetic
subjects [18]. By contrast, other studies have found differences in RNFL and GCL thickness when
comparing diabetic subjects to control subjects. A meta-analysis that included 8 studies with small
sample sizes concluded that retinal thinning may be present in diabetic subjects with mild DR or
no DR, leading those authors to suggest that retinal neurodegeneration may be considered an early
stage of DR that precedes visible retinal vasculopathy [19]. Other studies have compared young or
paediatric T1D subjects without DR to healthy control subjects and found significant thinning of the
RNFL [4,5,8] and the GCL [4,5,7,8] in diabetic patients. Gundogan et al. found that GCL thinning
was most prominent in the temporal sector, leading those authors to suggest that the temporal GCL
sectors are the most vulnerable in diabetic subjects and, thus, that data obtained by SD-OCT could be
used as biomarkers of retinal neurodegeneration in diabetic patients without DR [5]. We did observe a
significant thinning in the GCL of T1D subjects compared to the control subjects, although this change
was only significant for advanced DR, not for mild or no DR. However, we were unable to evaluate
these sectorial changes in the temporal GCL area because the SD-OCT instrument used does not allow
for this type of subanalysis. Van Dijk et al. found RNFL and GCL thinning in T1D subjects with mild
DR but not without DR compared to control subjects [6]. Their results suggest that thinning of the
inner retinal layers appears to occur at the expense of thinning of the GCL and later of the RNFL
due to loss of ganglion cell axons. These authors inferred that the nasal RNFL sector is the most
vulnerable in diabetic subjects, since ganglion cell axons travel in bundles to the head of the optic nerve
without crossing. We found similar changes in our series, with an intense thinning of the nasal RNFL
in T1D subjects without DR compared to control subjects as reported by other authors [8]. Notably,
this thinning was similar in subjects with advanced stages of DR. Importantly, this finding remained
statistically significant after adjustment for clinical variables in the multivariate regression analysis. It
is interesting to note that the presence of any sign of macular oedema was a strict exclusion criterion,
and, therefore, macular thickness (or the thickness of any of the inner retinal layer) was not affected
by this feature in our patients. Other authors obtained similar results in studies based on mfERG, in
which they found a longer P1-implicit time and a lower P1 amplitude in the nasal area than in the
temporal area in eyes of diabetic subjects [27,28].
More recently, the results reported in the European Consortium for the Early Treatment
of Diabetic Retinopathy (EUROCONDOR) study, which enrolled 449 participants with type 2
diabetes, pointed to the existence of two phenotypes of subjects: a group in which there is
neurodegeneration/neurodysfunction without microvascular involvement and another group of
subjects with microangiopathy but without neurodysfunction. The results of the study showed that
58% of subjects with neurodysfunction, evaluated by mfERG, had no evidence of visible retinopathy.
On the other hand, 32% of subjects with visible microvascular disease did not present any functional or
structural abnormalities related to neurodegeneration. This study also showed that the correspondence
between SD-OCT thinning and mfERG abnormalities in subjects without DR was 67% [26,29]. Our
results are in line with those reported in the EUROCONDOR study, in that there is a proportion of
subjects without DR who show SD-OCT evidence of neurodegeneration, while a proportion of subjects
with severe nonproliferative DR do not show SD-OCT evidence of neurodegeneration.
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4.2. Choroid
The choroid provides oxygen and nutrients to the outer retinal layers and is the only blood
supply of the avascular fovea [30]. In DR, several histopathological choroidal abnormalities have been
reported, including vascular remodelling with increased tortuosity, obstruction and dilatation of the
choriocapillaries, choroidal aneurysms, and choroidal neovascularisation. The association between
choroidal thickness and DR stage has been widely reported. Several studies have not found any
significant differences between T1D subjects and control subjects in terms of CT [8,9,16,24]. However,
this lack of difference could be due to the relatively recent onset of diabetes in the patients (mostly
paediatric) included in those studies. By contrast, other studies have found significant choroidal
thinning in T1D patients with [14] and without DR [5,14] compared to non-diabetic individuals.
Vusojevic et al. attributed this thinning to a relative vasoconstriction or decrease in perfusion pressure
in the choroidal vessels [15]. Our results—obtained in a large cohort of adult T1D subjects—differ
substantially from those of previous reports. We found a significant increase in CT in diabetic subjects
with mild DR and even in those without DR. Interestingly, while choroidal thickening was observed
in diabetic subjects without DR and in those with mild DR, the CT in patients with advanced DR
was similar to the CT in controls. A possible explanation for the CT difference observed in relation to
retinopathy grades may be related to inflammation. It has been suggested that polymorphonuclear
neutrophils might contribute to vaso-occlusive events and endothelial cell injury in the diabetic
choroid. In this way, the loss of choriocapillaries in the diabetic choroid could render those areas of the
choroid overlaying the retinal pigment epithelium (RPE) hypoxic [31]. When the RPE is hypoxic, it
upregulates VEGF (vascular endothelial growth factor) production, which stimulates angiogenesis [32].
Alternatively, the increase in CT could be interpreted as a hyper-vascularization stage similar to the
hyperfiltration that occurs in early stages of diabetic nephropathy. These findings suggest that changes
in choroidal vasculature could be an early event in the diabetic retina, even where there is no DR [33].
The thinner CT observed in the advanced stages of DR could be related to the progressive damage of
the endothelium that results from this process, causing reduced flow and ischaemia.
4.3. Study Strengths and Limitations
The present study has several limitations. First, despite the relatively large number of subjects
with T1D included in the study, after stratification by the degree of DR, the numbers in each category
were limited, especially in the advanced stages. Second, patients with a history of cardiovascular
disease, microalbuminuria, or diabetic foot disease were excluded from the study, thereby excluding
patients with other comorbidities. Third, the presence of retinal neurodegeneration was assessed by
SD-OCT to measure the inner retinal layer thickness (a morphological parameter), whereas the use of
other technologies based on the assessment of functional parameters (e.g., mfERG or microperimetry)
might exhibit different results. Fourth, the refractive error of the patients included in the study was
not recorded. Since myopic status could alter chorioretinal thickness, especially in high myopia, the
absence of data on refractive errors can also be added to the limiting factors. However, it should be
noted that all patients had less than 5.00 dioptres. Finally, the absence of patients without previous
established cardiovascular and/or renal disease does not enable us to extrapolate our findings to T1D
subjects with previous cardiovascular disease and/or chronic kidney disease.
This study also has several important strengths. First, this study included the largest cohort of
patients with T1D, in which SD-OCT was used to evaluate structural features of the retina. In addition,
it reports, for the first time, a direct correlation between choroidal alterations and the degree of diabetic
retinopathy in patients with T1D.
5. Conclusions
The current study, carried out on T1D patients, reveals a significant thinning of nasal RNFL, even
before any vascular changes in the retina can be detected by standard diagnostic techniques. GCL
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thickness was also decreased in T1D subjects with advanced DR compared to the control subjects.
In addition, while choroidal thickness was increased in T1D subjects with mild or no DR, the CT
thickness in subjects with advanced DR was similar to the CT values obtained from the control subjects.
Overall, our findings suggest that SD-OCT could be used as an early diagnostic imaging test to detect
diabetes-related retinal involvement.
Supplementary Materials: The following material is available online at http://www.mdpi.com/2077-0383/8/9/
1412/s1: Table S1: Clinical characteristics of the study population according to diabetic retinopathy grade; Table
S2: Ophthalmological variables in the study population by group; Table S3: Univariate and multivariate analysis
of the association between ophthalmological variables and type 1 diabetes with respect to the control group; and
Figure S1: Retinal nerve fibre layer (RNFL) measurements by spectral-domain optical coherence tomography:
(a) control subjects and (b) T1D subjects with mild DR. TEMP, temporal sector; SUP, superior sector; NAS, nasal
sector; INF, inferior sector.
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